Affordable Access

deepdyve-link
Publisher Website

Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease.

Authors
  • Vurture, Gregory1
  • Peyronnet, Benoit1, 2
  • Feigin, Andrew3
  • Biagioni, Milton C3
  • Gilbert, Rebecca3
  • Rosenblum, Nirit3
  • Frucht, Steven3
  • Di Rocco, Alessandro3
  • Nitti, Victor W1
  • Brucker, Benjamin M1
  • 1 Department of Urology, New York University School of Medicine, New York, New York.
  • 2 Department of Urology, University of Rennes, Rennes, France. , (France)
  • 3 The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, New York University School of Medicine, New York, New York.
Type
Published Article
Journal
Neurourology and Urodynamics
Publisher
Wiley (John Wiley & Sons)
Publication Date
Nov 01, 2018
Volume
37
Issue
8
Pages
2669–2677
Identifiers
DOI: 10.1002/nau.23717
PMID: 29767449
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To assess the safety and efficacy of intradetrusor onabotulinum toxin A injections for the treatment of overactive bladder (OAB) in patients with Parkinson's disease (PD). All PD patients who underwent intradetrusor injections of onabotulinum toxin A (BoNT-A) for storage symptoms between 2010 and 2017 were included in a retrospective study. A 100 U dose of BoNT-A (Botox®, Allergan Irvine, CA) was used for the first injection in all patients. The primary endpoint was clinical success defined as any subjective improvement in OAB symptoms self-assessed by the patients 4 weeks after the injections. Out of 24 patients analyzed, 19 reported improvement of their OAB symptoms 4 weeks after the first injection (79.2%) with complete resolution of urgency urinary incontinence in seven patients (29.1%; P < 0.001). The average post-void residual (PVR) increased significantly after the first injection from 17.6 to 125.3 mL (P < 0.001). Three of the patients had to start clean intermittent catheterization (CIC) after the first injection (12.5%). Out of 49 injections in total, only five caused incomplete bladder emptying requiring the use of CIC (10.2%). Higher pre-injection PVR was significantly associated with both a lower chance of symptomatic improvement (P = 0.04) and a higher risk of incomplete bladder emptying with institution of CIC (P = 0.047). Intradetrusor injections of BoNT-A 100 U appeared as a safe and effective option in PD patients with OAB symptoms and a low PVR before the injection. Higher preoperative PVR was the strongest predictor of both treatment failure and postoperative urinary retention requiring CIC. © 2018 Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times